Evidence map›Paper›PMID 27156054›Full record

ReviewIrish journal of medical science2017

From inflammation to cancer.

A Korniluk, O Koper, H Kemona, V Dymicka-Piekarska

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Irish journal of medical science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Neutrophil-To-Lymphocyte Ratio as a Prognostic Indicator in Thyroid Cancer.Cancer control : journal of the Moffitt Cancer Center
    Pooled it
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

A KornilukDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, Ul. Waszyngtona 15A, 15-276, Bialystok, Poland.
O KoperDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, Ul. Waszyngtona 15A, 15-276, Bialystok, Poland.
H KemonaDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, Ul. Waszyngtona 15A, 15-276, Bialystok, Poland.
V Dymicka-PiekarskaDepartment of Clinical Laboratory Diagnostics, Medical University of Bialystok, Ul. Waszyngtona 15A, 15-276, Bialystok, Poland. piekarskav@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe participation of inflammation in the progression of cancer for many years have been the subject of research.

methodsIn the 19th century, there was evidence that an acute inflammation may inhibit the development of cancer. However, chronic inflammation affects the progression of the disease.

resultsToday, it is known that inflammation and cancer use similar mechanisms of development such as severe cell proliferation or angiogenesis. It has been shown that prolonged presence of inflammatory cells and factors in the tumor microenvironment can accelerate its growth and inhibit apoptosis of transformed cells.

conclusionIn this article we present a brief history of the discovery mechanisms and potential links between acute and chronic inflammation and cancer.

Indexed as

ApoptosisCell ProliferationDisease ProgressionHumansInflammationNeoplasmsNeovascularization, PathologicAcute inflammationAdhesion moleculesCancerChronic inflammation

Identifiers

PMID27156054
PMCPMC5323483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.